Literature DB >> 16203287

inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.

Mihai Merzianu1, L Jeffrey Medeiros, Jorge Cortes, Cameron Yin, Pei Lin, Dan Jones, Armand Glassman, Hagop Kantarjian, Yang Huh.   

Abstract

Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR-ABL and CBFss-MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16203287     DOI: 10.1309/3HFE-16DK-MB1D-BFMN

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

Review 2.  Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.

Authors:  Soranobu Ninomiya; Nobuhiro Kanemura; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Toshiki Yamada; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2011-04-27       Impact factor: 2.490

3.  Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.

Authors:  Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

4.  Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities.

Authors:  Eunhee Han; Hyeyoung Lee; Myungshin Kim; Yonggoo Kim; Kyungja Han; Sung-Eun Lee; Hee-Je Kim; Dong-Wook Kim
Journal:  Blood Res       Date:  2014-03-24

5.  del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.

Authors:  C Cameron Yin; Lynne V Abruzzo; Xiaoyan Qiu; Effrosyni Apostolidou; Jorge E Cortes; L Jeffrey Medeiros; Gary Lu
Journal:  Cancer Genet Cytogenet       Date:  2009-07

6.  Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.

Authors:  Cheng-Cheng Ma; Ye Chai; Hui Ling Chen; Xin Wang; Ying Gao; Wan Li Hu; Xue Xiang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Authors:  Yuan-Yuan Wang; Wen-Jing Ding; Feng Jiang; Zi-Xing Chen; Jian-Nong Cen; Xiao-Fei Qi; Jian-Ying Liang; Dan-Dan Liu; Jin-Lan Pan; Su-Ning Chen
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.